Two-thirds of patients with moderate or severe plaque psoriasis had complete or nearly complete clearance at 4 months with an ...

The TYK2 inhibitor deucravacitinib (Sotyktu) showed clinical potential in two diseases other than psoriasis, according to ...

More than half of patients with fingernail psoriasis achieved complete fingernail clearance after 68 weeks of guselkumab treatment.

Two posters presented at the 2025 American Academy of Dermatology Annual Meeting highlighted the importance of improving ...

Johnson & Johnson’s once-daily oral peptide has bested Bristol Myers Squibb’s reigning oral psoriasis med Sotyktu in a ...

Alumis Inc.'s twice-a-day oral drug totally cleared the skin of telltale red, itchy patches in nearly 39% of 80 ...

Positive results were reported for Johnson & Johnson's psoriasis drug during.a late-breaking research session today at the ...

Scalp psoriasis can cause crusty patches or scales on the surface of the head. Find details about medicated shampoos, ...

Three months after Bristol Myers Squibb revealed the success of two phase 3 trials of its oral targeted therapy Sotyktu in ...

Scalp psoriasis is an autoimmune skin condition, while dandruff is often the result of oily or greasy hair. Here are the key ...

InnoCare Pharma (HKEX: 09969; SSE: 688428), a leading biopharmaceutical company focusing on the treatment of cancer and autoimmune diseases, announced ...

A once-daily, oral tyrosine kinase 2 inhibitor was safe and “highly effective” in adults with moderate to severe plaque ...